By 2031, the market for short bowel syndrome is expected to reach US$ 3.66 billion. Companies are expanding their production capabilities in fish oil-based emulsions for patients with intestinal failure-associated liver disease and liver cholestasis, in addition to GLP2 and growth hormones.
Short bowel syndrome can lead to Crohn's disease, small intestine injury, or trauma. Complications like this are contributing significantly to the expansion of the short bowel syndrome industry. The market is divided into GLP-2, glutamine, growth hormone, and other pharmacological types. GLP-2, which is marketed in the United States and Europe under the brand names Gattex and Revestive in Europe and other international markets, currently has the greatest market share in terms of medicine in the short bowel syndrome market.
Read more @ https://cmilatestinsights.blogspot.com/2022/03/short-bowel-syndrome-market-global.html
